Loading
Obesity / Overweight / Tirzepatide · Phase 2 Trial
ClinicalTrials.gov · September 8, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 2 master protocol study registration for chronic weight management evaluating multiple investigational agents (LY3305677, LY3841136, Tirzepatide, LY3549492, LY3532226) against placebo. The study is actively recruiting with an estimated 1481 participants; no clinical outcomes or safety data are yet reported, and results will not be available until all intervention-specific appendices are complete.
Phase 2, Interventional, Randomized, Parallel, Double masking, Screening purpose. Obesity, Overweight; age from 18 Years; to 75 Years. Intervention: LY3305677 Obesity ISA OXA1; LY3841136 Obesity ISA LAA1; LY3841136 Obesity ISA LAA2; LY3549492 Obesity ISA GN01; LY3549492 Obesity ISA GN02; Obesity ISA MC01. Compared with: Placebo. n = 1,481. 56 sites: United States, Argentina.
This is a Phase 2 master protocol study registration for chronic weight management evaluating multiple investigational agents (LY3305677, LY3841136, Tirzepatide, LY3549492, LY3532226) against placebo. The study is actively recruiting with an estimated 1481 participants; no clinical outcomes or safety data are yet reported, and results will not be available until all intervention-specific appendices are complete.
This is a registry record only; no efficacy, safety, or clinical outcome data are reported. Primary outcome measure is allocation-based, not a clinical or safety endpoint.
The source did not state who this applies to in practice.
This is a Phase 2 master protocol study registration with no results reported; enrollment is ongoing and primary outcomes are allocation metrics, not efficacy or safety findings.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06143956). This is a study registration, not published results. Lead sponsor: Eli Lilly and Company. Recruitment status: RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 1481 participants (ESTIMATED). Conditions: Obesity, Overweight. Interventions: DRUG: LY3305677; DRUG: LY3841136; DRUG: Tirzepatide; DRUG: LY3549492; DRUG: LY3532226; DRUG: Placebo; DRUG: Placebo. Primary outcome measures: Number of Participants Allocated to Each ISA , Baseline to Week 6. Brief summary: The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to evaluate the safety and efficacy of various investigational interventions for chronic weight management with intervention-specific appendices (ISAs). The CWMM establishes entry criteria for newly enrolled participants across the master and the ISAs. The ISAs may start independently of other ISAs as interventions become available for clinical testing. The results for the CWMM screening record will be reported when all the ISA's complete.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.